TScan Therapeutics Reports Q3 2026 Revenue of $0.6M and Net Loss of $33.1M
TScan Therapeutics reported third-quarter 2026 revenue of $0.6 million and a net loss of $33.1 million. The company is prioritizing in vivo-engineered TCR-T therapies for solid tumors, with its first clinical candidate targeted to enter a trial in the fourth quarter of 2027. Cash and cash equivalen…